BIOMAT Database Logo BIOMAT Database Logo

Cytokine dysregulation in chronic graft versus host disease. 1995

V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Department of Oncology, Hadassah University Hospital, Jerusalem, Israel.

Cytokines play a key role in the pathogenesis of chronic Graft versus Host Disease (cGVHD) and various studies have shown abberant production of cytokines by immune cells from GVHD patients. Based on these findings and others showing that high TNF levels precede the development of GVHD, we evaluated inflammatory cytokine levels following BMT and during the development of cGVHD. In this study, patients undergoing bone marrow transplantation (BMT) who consequently developed chronic GVHD were analyzed as to their cytokine production during cGVHD and this was correlated with their clinical manifestations. A positive correlation was found between the severity as well as the number of major clinical complications and high levels of inflammatory cytokines (IL-1 beta IL-6 and TNF alpha) compared to control patients or to normal donors. Patients undergoing BMT who did not develop GVHD, did not produce high levels of IL-1 beta IL-6 or TNF. High levels of cytokines may be used as a tool for assessing novel therapeutic modalities and response to GVHD treatment.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Cytokine Dysregulation in Acute Graft-versus-Host Disease.
January 1997, Hematology (Amsterdam, Netherlands),
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Cytokine dysregulation and acute graft-versus-host disease.
December 1992, Blood,
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Cytokine dysregulation as a mechanism of graft versus host disease.
October 1993, Current opinion in immunology,
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Cytokine mediators of chronic graft-versus-host disease.
June 2017, The Journal of clinical investigation,
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Protein dysregulation in graft versus host disease.
January 2018, Oncotarget,
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Cytokine expression in human cutaneous chronic graft-versus-host disease.
June 1996, Bone marrow transplantation,
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Cytokine gene expression in mice undergoing chronic graft-versus-host disease.
May 1993, Molecular immunology,
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Dysregulation of cytokines during graft-versus-host disease.
February 1996, Journal of hematotherapy,
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Cytokine inhibitors and graft-versus-host disease.
December 1995, Annals of the New York Academy of Sciences,
V Barak, and F Levi-Schaffer, and B Nisman, and A Nagler
Cytokine cascades in acute graft-versus-host disease.
August 1997, Transplantation,
Copied contents to your clipboard!